Cargando…

Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers

PURPOSE: The aim was to assess the feasibility of online adaptive radiotherapy (oART) for bladder cancer using a focal boost by focusing on the quality of the online treatment plan and automatic target delineation, duration of the workflow and performance in the presence of fiducial markers for tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Azzarouali, Sana, Goudschaal, Karin, Visser, Jorrit, Hulshof, Maarten, Admiraal, Marjan, van Wieringen, Niek, Nieuwenhuijzen, Jakko, Wiersma, Jan, Daniëls, Laurien, den Boer, Duncan, Bel, Arjan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557331/
https://www.ncbi.nlm.nih.gov/pubmed/37803392
http://dx.doi.org/10.1186/s13014-023-02348-8
_version_ 1785117067994726400
author Azzarouali, Sana
Goudschaal, Karin
Visser, Jorrit
Hulshof, Maarten
Admiraal, Marjan
van Wieringen, Niek
Nieuwenhuijzen, Jakko
Wiersma, Jan
Daniëls, Laurien
den Boer, Duncan
Bel, Arjan
author_facet Azzarouali, Sana
Goudschaal, Karin
Visser, Jorrit
Hulshof, Maarten
Admiraal, Marjan
van Wieringen, Niek
Nieuwenhuijzen, Jakko
Wiersma, Jan
Daniëls, Laurien
den Boer, Duncan
Bel, Arjan
author_sort Azzarouali, Sana
collection PubMed
description PURPOSE: The aim was to assess the feasibility of online adaptive radiotherapy (oART) for bladder cancer using a focal boost by focusing on the quality of the online treatment plan and automatic target delineation, duration of the workflow and performance in the presence of fiducial markers for tumor bed localization. METHODS: Fifteen patients with muscle invasive bladder cancer received daily oART with Cone Beam CT (CBCT), artificial intelligence (AI)-assisted automatic delineation of the daily anatomy and online plan reoptimization. The bladder and pelvic lymph nodes received a total dose of 40 Gy in 20 fractions, the tumor received an additional simultaneously integrated boost (SIB) of 15 Gy. The dose distribution of the reference plan was calculated for the daily anatomy, i.e. the scheduled plan. Simultaneously, a reoptimization of the plan was performed i.e. the adaptive plan. The target coverage and V(95%) outside the target were evaluated for both plans. The need for manual adjustments of the GTV delineation, the duration of the workflow and the influence of fiducial markers were assessed. RESULTS: All 300 adaptive plans met the requirement of the CTV-coverage V(95%)≥98% for both the boost (55 Gy) and elective volume (40 Gy). For the scheduled plans the CTV-coverage was 53.5% and 98.5%, respectively. Significantly less tissue outside the targets received 55 Gy in case of the adaptive plans as compared to the scheduled plans. Manual corrections of the GTV were performed in 67% of the sessions. In 96% of these corrections the GTV was enlarged and resulted in a median improvement of 1% for the target coverage. The median on-couch time was 22 min. A third of the session time consisted of reoptimization of the treatment plan. Fiducial markers were visible on the CBCTs and aided the tumor localization. CONCLUSIONS: AI-driven CBCT-guided oART aided by fiducial markers is feasible for bladder cancer radiotherapy treatment including a SIB. The quality of the adaptive plans met the clinical requirements and fiducial markers were visible enabling consistent daily tumor localization. Improved automatic delineation to lower the need for manual corrections and faster reoptimization would result in shorter session time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-023-02348-8.
format Online
Article
Text
id pubmed-10557331
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105573312023-10-07 Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers Azzarouali, Sana Goudschaal, Karin Visser, Jorrit Hulshof, Maarten Admiraal, Marjan van Wieringen, Niek Nieuwenhuijzen, Jakko Wiersma, Jan Daniëls, Laurien den Boer, Duncan Bel, Arjan Radiat Oncol Research PURPOSE: The aim was to assess the feasibility of online adaptive radiotherapy (oART) for bladder cancer using a focal boost by focusing on the quality of the online treatment plan and automatic target delineation, duration of the workflow and performance in the presence of fiducial markers for tumor bed localization. METHODS: Fifteen patients with muscle invasive bladder cancer received daily oART with Cone Beam CT (CBCT), artificial intelligence (AI)-assisted automatic delineation of the daily anatomy and online plan reoptimization. The bladder and pelvic lymph nodes received a total dose of 40 Gy in 20 fractions, the tumor received an additional simultaneously integrated boost (SIB) of 15 Gy. The dose distribution of the reference plan was calculated for the daily anatomy, i.e. the scheduled plan. Simultaneously, a reoptimization of the plan was performed i.e. the adaptive plan. The target coverage and V(95%) outside the target were evaluated for both plans. The need for manual adjustments of the GTV delineation, the duration of the workflow and the influence of fiducial markers were assessed. RESULTS: All 300 adaptive plans met the requirement of the CTV-coverage V(95%)≥98% for both the boost (55 Gy) and elective volume (40 Gy). For the scheduled plans the CTV-coverage was 53.5% and 98.5%, respectively. Significantly less tissue outside the targets received 55 Gy in case of the adaptive plans as compared to the scheduled plans. Manual corrections of the GTV were performed in 67% of the sessions. In 96% of these corrections the GTV was enlarged and resulted in a median improvement of 1% for the target coverage. The median on-couch time was 22 min. A third of the session time consisted of reoptimization of the treatment plan. Fiducial markers were visible on the CBCTs and aided the tumor localization. CONCLUSIONS: AI-driven CBCT-guided oART aided by fiducial markers is feasible for bladder cancer radiotherapy treatment including a SIB. The quality of the adaptive plans met the clinical requirements and fiducial markers were visible enabling consistent daily tumor localization. Improved automatic delineation to lower the need for manual corrections and faster reoptimization would result in shorter session time. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13014-023-02348-8. BioMed Central 2023-10-06 /pmc/articles/PMC10557331/ /pubmed/37803392 http://dx.doi.org/10.1186/s13014-023-02348-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Azzarouali, Sana
Goudschaal, Karin
Visser, Jorrit
Hulshof, Maarten
Admiraal, Marjan
van Wieringen, Niek
Nieuwenhuijzen, Jakko
Wiersma, Jan
Daniëls, Laurien
den Boer, Duncan
Bel, Arjan
Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
title Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
title_full Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
title_fullStr Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
title_full_unstemmed Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
title_short Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
title_sort online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557331/
https://www.ncbi.nlm.nih.gov/pubmed/37803392
http://dx.doi.org/10.1186/s13014-023-02348-8
work_keys_str_mv AT azzaroualisana onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT goudschaalkarin onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT visserjorrit onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT hulshofmaarten onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT admiraalmarjan onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT vanwieringenniek onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT nieuwenhuijzenjakko onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT wiersmajan onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT danielslaurien onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT denboerduncan onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers
AT belarjan onlineadaptiveradiotherapyforbladdercancerusingasimultaneousintegratedboostandfiducialmarkers